Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 114 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Doumas, Michael [Clear All Filters]
Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?.
Curr Treat Options Cardiovasc Med. 19(5), 39.
(2017). SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature..
Curr Pharm Des. 23(10), 1510-1521.
(2017). Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?.
J Neurol Neurosurg Psychiatry. 88(3), 249-253.
(2017). Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look at Additional Parameters..
JAMA Intern Med. 177(9), 1393.
(2017). Time in Therapeutic Range, as a Determinant of All-Cause Mortality in Patients With Hypertension..
J Am Heart Assoc. 6(11),
(2017).
(2017).
(2017). Antihypertensive drug treatment: the real-life challenge..
J Clin Hypertens (Greenwich). 20(1), 115-117.
(2018). Carotid intima-media thickness as a target-organ damage and treatment-target: Need for a major revision?.
J Clin Hypertens (Greenwich). 20(2), 255-257.
(2018). Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints..
Curr Pharm Des.
(2018). Diabetes and lipid metabolism..
Hormones (Athens). 17(1), 61-67.
(2018). Early Vascular Aging Risk Assessment From Ambulatory Blood Pressure Monitoring: The Early Vascular Aging Ambulatory Score..
Am J Hypertens. 31(11), 1197-1204.
(2018). Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality..
Curr Vasc Pharmacol. 16(3), 206-208.
(2018). Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis..
Curr Vasc Pharmacol. 16(2), 104-106.
(2018). Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension..
Curr Vasc Pharmacol. 16(4), 393-400.
(2018). Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes..
N Engl J Med. 378(10), 967.
(2018). Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?.
J Clin Hypertens (Greenwich). 20(3), 469-471.
(2018). The potential role of statins in treating liver disease..
Expert Rev Gastroenterol Hepatol. 12(4), 331-339.
(2018). Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?.
J Clin Hypertens (Greenwich). 20(5), 942-948.
(2018). Psoriasis and Cardiovascular Disease: Two Sides of the Same Coin?.
Angiology. 69(1), 5-9.
(2018). Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?.
Open Cardiovasc Med J. 12, 29-40.
(2018). Renal resistive index for renovascular hypertension: In the quest of the Holy Grail..
J Clin Hypertens (Greenwich). 20(3), 589-591.
(2018). Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?.
J Clin Hypertens (Greenwich). 20(4), 634-636.
(2018). Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension..
J Clin Hypertens (Greenwich). 20(1), 65-68.
(2018). Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease..
Cardiovasc Hematol Disord Drug Targets. 18(2), 120-126.
(2018).